Figure 1. Phase II Trial for SNG001 [44]. IFN-β is a natural antiviral that is produced in lungs during lung infections. However, this is reduced in older patients. Successful outcomes in this trial could be a breakthrough for helping older covid-19 patients

From

Current Challenges of the 2019-COVID Pandemic: Where We Started, Where We Are, and Where do We Go?

Tarek Khedro, George Yaghmour, Giridharan Ramsingh, Bassam Yaghmour

American Journal of Infectious Diseases and Microbiology. 2020, 8(2), 48-56 doi:10.12691/ajidm-8-2-2